BACKGROUND & AIMS: Hyperinsulinemia is a putative colorectal cancer (CRC) risk factor. Insulin resistance (IR) commonly precedes hyperinsulinemia and can be quantitatively measured by using the homeostasis model assessment-insulin resistance (HOMA-IR) index. To date, few studies have directly examined serum insulin as an indicator of CRC risk, and none have reported associations on the basis of HOMA-IR. METHODS: We performed a case-cohort study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study (n=29,133). Baseline exposure and fasting serum biomarker data were available for 134 incident CRC case and 399 non-case subjects. HOMA-IR was derived as fasting insulin x fasting glucose/22.5. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by using age-adjusted and multivariable-adjusted Cox proportional hazards regression models. RESULTS:Median (interquartile range) values for serum insulin, glucose, and HOMA-IR were 4.1 (2.9-7.2) mIU/L, 101 (94-108) mg/dL, and 0.99 (0.69-1.98) for case subjects and 4.1 (2.7-6.1) mIU/L, 99 (93-107) mg/dL, and 1.02 (0.69-1.53) for non-case subjects, respectively. On the basis of comparison of the highest versus lowest quartiles for each biomarker, insulin (HR, 1.84; 95% CI, 1.03-3.30) and HOMA-IR (HR, 1.85; 95% CI, 1.06-3.24) were significantly associated with incident CRC, whereas glucose was marginally associated with incident CRC (HR, 1.70; 95% CI, 0.92-3.13) in age-adjusted risk models. However, trends across biomarker quartiles were somewhat inconsistent (P trend=.12, .04, and .12, respectively), and multivariable adjustment generally attenuated the observed risk estimates. CONCLUSIONS: Data from this prospective study of male smokers provide limited support for hyperinsulinemia, hyperglycemia, and/or insulin resistance as CRC risk factors.
RCT Entities:
BACKGROUND & AIMS:Hyperinsulinemia is a putative colorectal cancer (CRC) risk factor. Insulin resistance (IR) commonly precedes hyperinsulinemia and can be quantitatively measured by using the homeostasis model assessment-insulin resistance (HOMA-IR) index. To date, few studies have directly examined serum insulin as an indicator of CRC risk, and none have reported associations on the basis of HOMA-IR. METHODS: We performed a case-cohort study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study (n=29,133). Baseline exposure and fasting serum biomarker data were available for 134 incident CRC case and 399 non-case subjects. HOMA-IR was derived as fasting insulin x fasting glucose/22.5. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by using age-adjusted and multivariable-adjusted Cox proportional hazards regression models. RESULTS: Median (interquartile range) values for serum insulin, glucose, and HOMA-IR were 4.1 (2.9-7.2) mIU/L, 101 (94-108) mg/dL, and 0.99 (0.69-1.98) for case subjects and 4.1 (2.7-6.1) mIU/L, 99 (93-107) mg/dL, and 1.02 (0.69-1.53) for non-case subjects, respectively. On the basis of comparison of the highest versus lowest quartiles for each biomarker, insulin (HR, 1.84; 95% CI, 1.03-3.30) and HOMA-IR (HR, 1.85; 95% CI, 1.06-3.24) were significantly associated with incident CRC, whereas glucose was marginally associated with incident CRC (HR, 1.70; 95% CI, 0.92-3.13) in age-adjusted risk models. However, trends across biomarker quartiles were somewhat inconsistent (P trend=.12, .04, and .12, respectively), and multivariable adjustment generally attenuated the observed risk estimates. CONCLUSIONS: Data from this prospective study of male smokers provide limited support for hyperinsulinemia, hyperglycemia, and/or insulin resistance as CRC risk factors.
Authors: Laura A Colangelo; Susan M Gapstur; Peter H Gann; Alan R Dyer; Kiang Liu Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-04 Impact factor: 4.254
Authors: Sharon H Saydah; Elizabeth A Platz; Nader Rifai; Michael N Pollak; Frederick L Brancati; Kathy J Helzlsouer Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-05 Impact factor: 4.254
Authors: Ying Bao; Katharina Nimptsch; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Dominique S Michaud; Jennie C Brand-Miller; Walter C Willett; Edward Giovannucci; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-05 Impact factor: 4.254
Authors: Xiaosheng He; Kana Wu; Xuehong Zhang; Reiko Nishihara; Yin Cao; Charlie S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan; Mingyang Song Journal: Int J Cancer Date: 2019-05-21 Impact factor: 7.396
Authors: Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon Journal: Cancer Prev Res (Phila) Date: 2016-08-29
Authors: Akiko Hanyuda; Sun A Kim; Alejandro Martinez-Fernandez; Zhi Rong Qian; Mai Yamauchi; Reiko Nishihara; Teppei Morikawa; Xiaoyun Liao; Kentaro Inamura; Kosuke Mima; Yin Cao; Xuehong Zhang; Kana Wu; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Ramesh A Shivdasani; Shuji Ogino Journal: Ann Surg Oncol Date: 2015-11-17 Impact factor: 5.344
Authors: Demetrius Albanes; Stephanie J Weinstein; Margaret E Wright; Satu Männistö; Paul J Limburg; Kirk Snyder; Jarmo Virtamo Journal: J Natl Cancer Inst Date: 2009-08-21 Impact factor: 13.506
Authors: J H Rubenstein; J Y Kao; R D Madanick; M Zhang; M Wang; M B Spacek; J L Donovan; S D Bright; N J Shaheen Journal: Gut Date: 2009-06-30 Impact factor: 23.059